12.11.2020 - 12.11.2020 MS Matters: Treatment strategies and sequencing – an insight into COVID-19 considerations
Accurate classification of people with multiple sclerosis (MS) is essential for personalised treatment decisions; however, a consensus on how to classify people with MS as ‘high-‘ or ‘low-risk’ is lacking.1 Furthermore, the range of disease-modifying therapy options available for the management of people with MS makes achieving the optimal treatment strategy or sequence a challenge, and this is an area of active research.2–4 In the context of the COVID-19 pandemic, the challenge of effectively managing people with MS, whilst avoiding exposing them to unjustified infection risk is a further consideration for the MS management team.
These topics and more will be discussed in the fourth MS Matters webinar of 2020, in an interactive discussion between Professors Ralf Gold and Heinz Wiendl. The two experts will be examining data on different MS treatment strategies and sequencing approaches and discussing how these approaches are being modified due the COVID-19 pandemic and the emergence of a potential vaccine.
You will have opportunities to ask questions to the faculty throughout the webinar. We look forward to welcoming you at this online event and we anticipate an engaging discussion with implications for clinical practice.
Please click the button below to register.
Montalban X, et al. Mult Scler 2018;24:96–120.
Filippi M, Rocca MA. Lancet Neurol 2020;19:281–2.
Ontaneda D, et al. Contemp Clin Trials 2020;106009.
Lancet Neurol 2020;19:281–2; 3. Ontaneda D, et al. Contemp Clin Trials 2020;106009; 4. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03500328. Accessed July 2020.